What's Happening?
Brown University researchers have concluded the first study on MDMA-assisted therapy for military veterans suffering from both post-traumatic stress disorder (PTSD) and alcohol use disorder. The findings, published in the journal *Alcohol*, indicate that
this novel therapy is safe, feasible, and tolerable for participants. Preliminary evidence also suggests significant improvements in both PTSD symptoms and alcohol-related outcomes. Study co-author Christy Capone, an assistant professor of psychiatry and human behavior (research) at Brown University's Warren Alpert Medical School, noted that the results exceeded expectations. The program involved 11 therapy sessions over five months, including three preparatory sessions, two MDMA administration sessions alongside psychotherapy, and six integration sessions. Nine out of ten enrolled participants completed the full intervention and follow-up, a notable retention rate given the time commitment and the difficulty in retaining participants in other veteran treatment programs. Participants showed a mean reduction of over 22 points on the Clinician-Administered PTSD Scale for DSM-5 (CAPS-5), moving from severe to mild PTSD symptom severity. While alcohol consumption decreased, these changes were not deemed clinically significant due to some participants reducing drinking before the trial and the absence of a control group. No serious adverse events were reported.
Why It's Important?
This research is crucial for U.S. military veterans, a population disproportionately affected by co-occurring PTSD and alcohol use disorder. This combination leads to greater symptom severity, functional impairment, and poorer outcomes compared to either disorder alone. Existing treatments, such as trauma-focused psychotherapies and cognitive processing therapy, often show only modest effectiveness, with persistent challenges in engagement and sustained improvement. The promising results from this MDMA-assisted therapy study offer a potential new and more effective treatment option for a high-risk group. The high completion rate of the program, despite its intensity, highlights its feasibility and tolerability among veterans, addressing a significant barrier in current treatment models. The substantial reduction in PTSD symptoms observed in the study could lead to improved quality of life and reduced suicide risk among veterans, a critical public health concern. The study also provides further evidence for the therapeutic potential of MDMA, which the U.S. Food and Drug Administration (FDA) had previously designated as a breakthrough therapy for PTSD, despite declining approval in 2024 due to efficacy and methodological concerns. This new data could contribute to a stronger evidence base for future regulatory approval.
What's Next?
The researchers plan to release findings from brain scans collected during the study to measure and compare biomarkers of PTSD before and after treatment. This will provide a deeper understanding of the neurological impacts of the therapy. Additionally, the team is collaborating with the Providence VA Medical Center on a larger, randomized clinical trial. This upcoming trial will compare a therapeutic dose of MDMA with a low dose serving as an active control condition, aiming to further solidify the evidence base for this intervention. Such rigorous, well-controlled trials are essential to address the FDA's previous concerns and could pave the way for eventual regulatory approval of MDMA-assisted therapy for PTSD, particularly for underrepresented populations like veterans with co-occurring alcohol use disorder. The long-term vision is to establish this intervention as a widely accessible and effective treatment, potentially transforming care for veterans struggling with these complex conditions.
Beyond the Headlines
The potential widespread adoption of MDMA-assisted therapy for PTSD and alcohol use disorder in veterans could signify a paradigm shift in mental health treatment. This approach moves beyond traditional pharmacological interventions by integrating psychotherapy with a psychedelic compound, challenging long-held stigmas associated with such substances. The success of this therapy could open doors for research into other psychedelic-assisted treatments for various mental health conditions, potentially revolutionizing psychiatric care. However, the ethical and legal frameworks surrounding the use of controlled substances in therapy will require careful consideration and development. The integration of such therapies into mainstream healthcare, particularly within the Veterans Health Administration, would necessitate comprehensive training for therapists, robust oversight mechanisms, and equitable access to ensure that all veterans who could benefit receive this innovative care. This development also underscores the urgent need for continued investment in mental health research, especially for vulnerable populations like veterans, to explore novel and more effective treatment modalities.













